Acumen will present patient experience, data from Phase 1 INTERCEPT-AD study

Acumen Pharmaceuticals announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug at the Alzheimer’s Association International Conference, AAIC, 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid, and provide insights on patients’ experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug. Sabirnetug is the first humanized monoclonal antibody to demonstrate in patients with early symptomatic AD selective target engagement of AbetaOs, a soluble and highly toxic form of Abeta that accumulates early in AD and is a persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early symptomatic AD.